Fly News Breaks for September 10, 2019
Sep 10, 2019 | 13:43 EDT
JMP Securities analyst Jason Butler reiterated an Outperform rating and $21 price target on Intra-Cellular following the announcement that the FDA does not plan to schedule an Advisory Committee meeting to discuss lumateperone for schizophrenia. In a research note to investors, Butler says he remains confident that the company has adequately addressed the FDA's questions and maintains his expectation for a "successful" NDA review and approval of lumateperone by the PDUFA date.
News For ITCI From the Last 2 Days
There are no results for your query ITCI